The International AIDS Vaccine Initiative (IAVI), GlycoMimetics (GMI), and Glycosensors and Diagnostics (G&D) have collaborated to develop a vaccine against AIDS.
The project being funded by IAVI's Innovation Fund will integrate the specialized design capabilities of GMI, the novel biomolecular simulation technology of G&D with the vaccine design expertise of Oxford University and IAVI's anti-carbohydrate antibodies.
The aim of the project is to develop carbohydrate immunogens capable of stimulating protective antibody responses to HIV.
IAVI New Alliances director Hansi Dean said the effort combines the advanced technology and expertise from four diverse partners to address a major challenge in HIV vaccine design, that target the carbohydrate layer which shields the virus from the immune system.
GMI vice president and chief scientific officer John Magnani said the project provides an opportunity to apply the company's specialized chemistry expertise to help address current unmet needs in the prevention and treatment of HIV and AIDS.